Generalized Myasthenia Gravis
Conditions
Brief summary
Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at Week 24
Detailed description
• Change from baseline in MG Quality of Life scale (MG-QOL15r) at Week 24, • Proportion of patients with a decrease of ≥2 points from baseline in MG-ADL score at Week 24, • Proportion of patients with a decrease of ≥3 points from baseline in QMG score at Week 24, • Proportion of patients who achieved minimal symptomatic expression (MSE, defined as having MG-ADL score of 0 or 1) at Week 24, Change from baseline in Quantitative Myasthenia Gravis (QMG) score at Week 24
Interventions
DRUGPlacebo contains excipients only and is visually indistinguishable from the Telitacicept
Sponsors
Vor Biopharma Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at Week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| • Change from baseline in MG Quality of Life scale (MG-QOL15r) at Week 24, • Proportion of patients with a decrease of ≥2 points from baseline in MG-ADL score at Week 24, • Proportion of patients with a decrease of ≥3 points from baseline in QMG score at Week 24, • Proportion of patients who achieved minimal symptomatic expression (MSE, defined as having MG-ADL score of 0 or 1) at Week 24, Change from baseline in Quantitative Myasthenia Gravis (QMG) score at Week 24 | — |
Countries
Belgium, Czechia, Denmark, France, Italy, Poland, Spain
Outcome results
None listed